Atlas Trials

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

Clinical trial NCT05025488 · RECRUITING

Trial details

NCT number
NCT05025488
Sponsor
Marina Kremyanskaya
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
MyelofibrosisEssential ThrombocythemiaMPN
Start date
2023-04-04
Primary completion
2027-03-01
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.